Proof-of-concept study to enumerate large oncosomes using the RareCyte CTC platform

April 8, 2024

Eszter Papp, Jo Vandesompele, Peter B. Vermeulen, Luc Y. Dirix, Mark Kockx

CellCarta’s proof-of-concept study utilizes the RareCyte CTC platform to enumerate large oncosomes (LOs) in patients with HER2 overexpressing tumors.

The study demonstrates that combining circulating tumor cells (CTCs), LOs, and circulating cell-free DNA (cfDNA) in a multimodal liquid biopsy analysis enhances the detection and monitoring of HER2 amplification in metastatic breast cancer.

The results showed a strong correlation between LO count and CTC count, and the combined analysis improved the accuracy of HER2 status assessment. This approach offers a cost-efficient and non-invasive method to monitor tumor biomarkers, providing valuable insights into tumor progression and treatment response.

View the poster:

Proof-of-concept study to enumerate large oncosomes using the RareCyte CTC platform